Höchst: Inside the sprawling chemical park on the western edge of Frankfurt, Sanofi runs one of the few insulin production sites left in Europe. Berlin wants a second one built there, wants it to keep running whether or not the economics work, and has just persuaded the Commission that paying for all of it counts as compensating a public service rather than subsidising a company.
The Commission cleared the measure on 8 September. Germany may pay Sanofi-Aventis Deutschland up to €400 million under Article 106(2) of the Treaty, the provision that lets member states fund services of general economic interest. In exchange the company must build a new insulin facility, guarantee a minimum annual output of human insulin and insulin analogues, and hold a strategic stockpile. The obligations run until 2042.
That legal route matters far more than the headline sum. Most pharmaceutical aid arrives through research subsidies, IPCEI projects or the temporary crisis frameworks, all of which the Commission assesses for distortive effect and then waves through with conditions. Article 106(2) works differently. It treats the recipient as a utility discharging a duty the state has defined, and it asks only whether the compensation exceeds the net cost of that duty. Once a supply obligation qualifies as a public service, the analysis shifts from whether the aid distorts competition to whether the payment is proportionate.
European insulin supply gives Berlin a plausible case. A handful of manufacturers serve the entire global market. Production concentrates in a small number of plants, and several sit outside the union. Diabetes patients cannot substitute or wait. When the Commission and member states drew up their pharmaceutical resilience agenda after the shortages of 2022 and 2023, insulin appeared on every list of molecules where a single plant failure would cascade across borders within weeks.
Competition lawyers will still read the decision carefully, because it sets a reference point. If securing insulin supply constitutes a service of general economic interest, the same argument extends to antibiotics, to saline solutions, to the generic injectables whose margins have driven producers out of Europe for a decade. Any national government with a resilience strategy and a willing manufacturer now has a template. Ministries in Paris, Madrid and Rome have all published lists of critical medicines they want produced domestically.
The risk is not that one factory distorts the insulin market. The risk is fragmentation. Twenty-seven governments each compensating a national champion for holding stockpiles would rebuild exactly the patchwork of subsidised national production that the single market was supposed to dissolve. Member states with fiscal room would secure supply; those without would depend on neighbours whose obligations stop at their own borders. The Commission has tools to police that, including the proportionality test and the sixteen-year duration it accepted here, but each individual case will look defensible on its own terms.
Sanofi gets something valuable beyond the money. A minimum-production mandate backed by state compensation removes the commercial question that closes plants: what happens when a competitor undercuts you. The company effectively secures a floor under a low-margin business for sixteen years.
Whether patients get anything depends on details the decision summary does not reveal. A stockpile helps only if the release triggers work and someone audits them. Minimum annual production helps only if the volume matches European demand rather than the company’s existing output. The full non-confidential text, due in the Commission’s state aid register in the coming weeks, will show how tightly Berlin drafted those obligations, and how much of the €400 million buys genuine additional resilience.
